Breast cancer can affect both women and men, although its burden falls disproportionately on women. According to the National Cancer Institute, women in the United States face approximately a one-in-eight lifetime risk of developing the disease. In 2026, an estimated 321,910 women are expected to receive a breast cancer diagnosis, while approximately 42,140 women are expected to die from it. An estimated 2,670 men will also be diagnosed. At the same time, the outlook has improved substantially: the breast cancer mortality rate among women has declined by 44% since 1989, according to the Susan G. Komen Foundation. That reduction reflects decades of advances in mammography, tumor biology, surgery, radiation, chemotherapy, endocrine therapy, targeted drugs, and immunotherapy, as well as the participation of patients in trials that test how these tools should be used.

One of the Alliance’s major studies is A012103, known as OptimICE-PCR, a Phase III trial for people with early-stage triple-negative breast cancer who achieve a pathologic complete response after preoperative chemotherapy combined with pembrolizumab. Triple-negative breast cancer lacks three molecular targets commonly used to guide treatment—the estrogen receptor, progesterone receptor, and HER2—making chemotherapy and immunotherapy important components of care for many patients. A pathologic complete response, or pCR, means that no invasive cancer is detected in tissue removed during surgery after neoadjuvant treatment. The study is testing whether patients who reach that milestone can stop pembrolizumab after surgery instead of continuing treatment for as long as 27 additional weeks. Pembrolizumab is an immune-checkpoint inhibitor that blocks the PD-1 pathway, helping immune cells remain active against tumor cells. If carefully selected patients can maintain similar outcomes with less exposure, the findings could reduce immune-related toxicities, treatment time, and financial burden.

A parallel Phase III study, Alliance A012303, or ShortStop-HER2, is examining treatment de-escalation in early-stage HER2-positive breast cancer. HER2 is a growth-promoting protein found at high levels on some breast cancer cells, and drugs that block its signaling have dramatically improved outcomes. However, standard adjuvant HER2-targeted therapy commonly continues for 12 months, even when a patient has already received preoperative treatment and achieves a pathologic complete response. ShortStop-HER2 is evaluating whether six months of postoperative HER2-directed therapy can provide the same protection against recurrence as the conventional 12-month approach in this specific group. The scientific challenge is to identify patients whose response to initial therapy indicates a sufficiently low residual risk while preserving the benefits of targeted treatment. A successful result could make treatment shorter without compromising effectiveness, but the trial’s randomized evidence will be essential before any change to routine practice.

The Alliance is also investigating how cancer treatment affects the body beyond the tumor itself. The A222302 DEFEND trial is evaluating whether a structured exercise program delivered entirely through telehealth can help patients receiving chemotherapy preserve physical function, reduce fatigue, and prevent disability. Chemotherapy can contribute to muscle loss, reduced cardiorespiratory fitness, neuropathy, fatigue, and decreased ability to perform everyday activities. These effects may be intensified by inactivity, yet treatment schedules and geographic distance can make in-person rehabilitation difficult. By using remote coaching and digitally delivered exercise support, the study is testing whether physical activity can be integrated into cancer care at a distance. Outcomes such as functional performance, fatigue, and disability are clinically meaningful because survival is only one measure of treatment success; maintaining independence and quality of life can determine how well patients recover during and after therapy.

For people who have completed breast cancer treatment, the Alliance is addressing complications that are common but often overlooked. Alliance A221801, the Revitalize trial, is a Phase III study led by Maryam Lustberg of Yale University Comprehensive Cancer Center that is evaluating fractional carbon dioxide laser therapy for vaginal dryness and vaginal atrophy in breast cancer survivors. Menopause, aging, and treatments that suppress estrogen can thin and dry vaginal tissues, producing discomfort, pain during sexual activity, urinary symptoms, and a major reduction in quality of life. Fractional CO₂ lasers deliver controlled energy to small areas of tissue, creating microscopic treatment zones intended to stimulate remodeling and healing. The trial is designed to determine whether this procedure provides meaningful and durable relief for breast cancer survivors, a population in which treatment decisions can be complicated by concerns about hormone exposure and recurrence risk. Rigorous comparison in a Phase III setting is needed to distinguish a true therapeutic benefit from placebo effects or temporary improvement.

Another survivorship study, Alliance A211901, known as Project Reach, focuses on smoking cessation among cancer survivors living in rural communities. Led by Devon Noonan of Duke University School of Nursing, the Phase III trial is evaluating a text-based intervention designed to help participants stop smoking. Tobacco use can worsen cardiovascular and pulmonary health, interfere with recovery, and contribute to the risk of additional cancers and other serious diseases. Rural survivors may face limited access to cessation counselors, transportation difficulties, shortages of oncology services, and inconsistent broadband access. Text messaging offers a relatively low-cost method for delivering reminders, behavioral strategies, motivational support, and connections to cessation resources. The trial will help determine whether a scalable, mobile intervention can reach survivors who are often underrepresented in research and whether supporting cessation can become a more routine part of survivorship care.

The Alliance’s prevention and early-detection research includes A212102, a study creating a blinded reference set for multicancer early-detection blood tests. These tests seek molecular signals released by tumors into the bloodstream, including fragments of DNA, RNA, proteins, or other biological markers, and use computational models to estimate whether cancer may be present and where it originated. The study is collecting and storing blood and tissue samples from people with and without cancer so researchers can evaluate how accurately such tests identify disease while controlling for false-positive results. Breast cancer is among the cancers represented. This type of reference resource is essential because a screening test must be assessed in populations that include healthy participants and people with different diseases, not only in patients already known to have cancer. Detecting cancer earlier could improve outcomes, but testing must also demonstrate that it leads to better health rather than unnecessary biopsies, anxiety, overdiagnosis, or treatment of tumors that would never have caused harm.

The A232301CD AYA Access Study is examining another barrier to prevention: access to genetic counseling and testing among adolescents and young adults with a history of cancer. Led by Angela Bradbury of the University of Pennsylvania Abramson Cancer Center, the study is testing an enhanced eHealth and chatbot-enabled model that combines online genetic education with at-home testing. Genetic information can identify inherited variants associated with elevated breast cancer risk, including changes in genes involved in DNA repair and tumor suppression. Yet young adults may encounter long waits, travel requirements, cost concerns, limited specialist availability, or uncertainty about whether genetic services apply to them. A digital model could make information and testing more accessible, while also helping participants understand the limits of genetic results, the possibility of uncertain findings, and implications for relatives. The study is particularly relevant to young breast cancer survivors, for whom genetic risk may influence surveillance, preventive surgery, treatment choices, and family counseling.

Together, these studies illustrate why clinical research remains central to breast cancer progress. The Alliance for Clinical Trials in Oncology connects more than 26,000 cancer specialists at 112 main institutions and approximately 1,400 affiliated sites across the United States and Canada. As part of the National Clinical Trials Network and a leading research base for the NCI Community Oncology Research Program, it conducts studies that can change treatment standards, generate high-impact scientific publications, and support regulatory decisions. More than 40,000 participants have taken part in Alliance studies, while its biospecimen repository contains more than 1.5 million samples collected over three decades. Each trial addresses a different point on the cancer continuum, from risk and early detection to treatment response, physical function, sexual health, and long-term survivorship. The combined goal is not simply to help more people survive breast cancer, but to ensure that they can live longer with fewer side effects, less disability, and more personalized care.

Subject of Research: Breast cancer clinical research, treatment de-escalation, survivorship, early detection, prevention, exercise, smoking cessation, and genetic services.

Web References: https://clinicaltrials.gov/study/NCT05812807; https://clinicaltrials.gov/study/NCT06876714; https://clinicaltrials.gov/study/NCT07059884; https://clinicaltrials.gov/study/NCT05379153; https://clinicaltrials.gov/study/NCT05008848; https://clinicaltrials.gov/study/NCT05334069; https://clinicaltrials.gov/study/NCT07091617; https://www.allianceforclinicaltrialsinoncology.org/

References: National Cancer Institute; Susan G. Komen Foundation; Alliance for Clinical Trials in Oncology.

Image Credits: The Alliance for Clinical Trials in Oncology.

Keywords: Breast cancer, cancer research, clinical trials, triple-negative breast cancer, HER2-positive breast cancer, pembrolizumab, immunotherapy, treatment de-escalation, survivorship, telehealth exercise, early detection, multicancer detection, genetic testing, smoking cessation.

Breast cancer remains one of the most prevalent malignancies globally, and its heterogeneity demands a nuanced approach to detection and treatment. The ER-positive and HER2-negative subtypes represent a substantial fraction of breast cancers diagnosed and are characterized by their unique hormonal receptor profiles and response patterns. Routine mammography, a radiographic technique designed to identify breast abnormalities before physical symptoms arise, has been advocated in numerous guidelines but remains variably utilized, particularly among older adults who may face barriers to screening. This study’s findings suggest that consistent screening within this subgroup not only facilitates detection at an earlier stage but also correlates with improved survival metrics, underscoring the potential life-extending benefits of mammographic surveillance.

The researchers employed a longitudinal observational design, tracking outcomes in a cohort of older women with previously undiagnosed ER-positive/HER2-negative breast cancer. Data indicated that those undergoing regular mammography screening had tumors detected at earlier clinical stages compared to counterparts with no prior screening history. This earlier stage at diagnosis is crucial as it allows for more effective intervention and less aggressive treatment regimens, which can be particularly beneficial in older patients who often contend with comorbidities and diminished physiological reserve. The association between screening and reduced mortality emphasizes the importance of integrating routine imaging protocols for breast cancer surveillance in geriatric oncology practice.

From a methodological perspective, the study leveraged rigorous statistical models to adjust for confounding factors inherent in observational research, such as health-seeking behavior and socioeconomic variables. Despite these adjustments, the authors prudently acknowledge that residual confounding cannot be entirely excluded. Differences beyond screening participation may influence the ultimate outcomes, a limitation typical to such non-randomized studies. Nevertheless, the robust association between mammography and favorable prognostic factors lends strong support to the causal link between early detection and survival benefits.

At a molecular level, ER-positive breast cancers respond to estrogen signaling, which drives tumor proliferation. Mammography’s ability to identify these tumors early provides clinicians with an opportunity to deploy targeted endocrine therapies, such as selective estrogen receptor modulators or aromatase inhibitors, earlier in the treatment continuum. HER2-negative status indicates the absence of overexpression of the HER2 protein, which is involved in cellular growth pathways. This subtype tends to have a more indolent progression but requires hormone-based intervention rather than HER2-targeted agents. The study’s results reinforce that timely detection via screening mammography acts as a gateway to optimized tailored treatment regimens.

The implications of this research are particularly salient given the aging global population and the increasing incidence of breast cancer in older adults. Historically, screening recommendations for older women have been contentious, given varying benefits versus risks such as overdiagnosis and overtreatment. This study provides vital empirical evidence advocating for the reconsideration and possibly the expansion of routine screening guidelines to encompass older women more explicitly, balancing the nuanced trade-offs with enhanced survival outcomes.

Moreover, the research calls attention to the need for healthcare systems and policy makers to mitigate barriers to screening access in the elderly. Socioeconomic factors, mobility challenges, and healthcare provider biases may contribute to suboptimal screening rates. By highlighting tangible mortality reductions tied to screening history, this study serves as a clarion call for integrated public health strategies aimed at uplifting mammography rates within this vulnerable cohort.

The cohort design of this study permits the observation of long-term trends and outcomes, presenting a real-world perspective often lost in randomized controlled trials. While randomized studies remain the gold standard for causal inference, the current findings derived from observational data complement and enrich the collective scientific narrative, particularly in understudied populations. The authors emphasize that despite the inherent limitations of observational data, the congruence of results with biological plausibility and existing literature strengthens the case for mammographic screening in older women.

In addition, the emphasis on breast cancer subtype specificity—focusing on ER-positive and HER2-negative tumors—provides critical context for interpreting the outcomes. Breast cancer is not monolithic; each molecular subtype exhibits distinct natural history and treatment responsiveness. Targeted studies like this one refine screening and management algorithms, paving the way for precision medicine approaches that tailor interventions not only to individual patient characteristics but also to tumor biology.

Clinicians and oncologists should take note of these findings as they suggest a paradigm shift—underscoring mammographic surveillance as more than a diagnostic tool but as an integral component of breast cancer management that can alter disease trajectory and improve survival outcomes. The study advocates for vigilant integration of routine screening in clinical pathways for older women presenting with risk factors for breast cancer.

Public awareness campaigns could harness the momentum generated by these findings to address misinformation and encourage older women to engage proactively in breast cancer screening programs. Tailored communication addressing the benefits, limitations, and safety of mammography may alleviate apprehensions and enhance uptake. Ultimately, such interventions could translate into more equitable health outcomes and reduced breast cancer mortality across demographics.

Future research prompted by this study can explore the mechanistic underpinnings of improved survival with routine screening, investigating how earlier detection influences tumor microenvironment, metastatic potential, and response to hormone therapies. Furthermore, translational studies integrating patient-reported outcomes and quality-of-life metrics will be essential to establish comprehensive benefits of screening beyond survival statistics.

In summary, this cohort study presents compelling evidence that routine screening mammography plays a vital role in early detection and mortality reduction for older women with ER-positive, HER2-negative breast cancer. While acknowledging the limitations intrinsic to observational data, the strength and consistency of these associations provide critical impetus for clinicians, researchers, and policymakers to prioritize mammographic screening in this demographic. As breast cancer continues to pose a formidable global health challenge, advances in early detection offer a tangible beacon of hope for improved patient outcomes.

Subject of Research: The impact of prior screening mammography on breast cancer stage at diagnosis and mortality among older women with estrogen receptor–positive, human epidermal growth factor receptor 2–negative breast cancer.

Article Title: Not provided.

News Publication Date: Not provided.

Web References: Not provided.

References: (doi:10.1001/jamanetworkopen.2025.5322)

Keywords: Breast cancer, Cancer screening, Cohort studies, Estrogen, Epidermis, Growth factor receptors, Mammography, Mortality rates, Older adults, Women’s studies, Observational studies, Cancer, Oncology, Medical histories